ESR1 and breast cancer: Regarding ERα-positive breast cancer, SETD7 enhances the transcriptional activity of ERα; therefore, SETD7 inhibitors could also synergize with endocrine therapy, and their applicability for treating ERα-positive/endocrine-resistant breast cancer should be investigated.